home / stock / cdtx / cdtx news

CDTX News and Press, Cidara Therapeutics Inc. From 06/26/23

Stock Information
Company Name: Cidara Therapeutics Inc.
Stock Symbol: CDTX
Market: NASDAQ
Website: cidara.com
Menu
CDTX CDTX Quote CDTX Short CDTX News CDTX Articles CDTX Message Board
Get CDTX Alerts

News, Short Squeeze, Breakout and More Instantly...
CDTX - Cidara Therapeutics joins Russell Microcap

2023-06-26 13:22:15 ET Cidara Therapeutics ( NASDAQ: CDTX ) said Monday it has joined the broad market Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution. Press Release . For further details see: Cida...
CDTX - Cidara Therapeutics Added to Russell Microcap® Index

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, announced today it has joined the broad market Russell M...

CDTX - Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administrati...

CDTX - Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation...
CDTX - Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation...

CDTX - Buy Cidara Therapeutics For Data Readout And European Foothold

2023-05-21 04:41:46 ET Summary With their first product approval last quarter, Europe should follow suit. Their U.S. partner is experienced in commercializing antibiotics. Their second drug candidate is likely to succeed in Phase 2. Cidara Therapeutics ( CDTX ) i...

CDTX - Cidara Therapeutics GAAP EPS of $0.03 beats by $0.07, revenue of $25.99M beats by $7.31M

2023-05-11 17:29:33 ET Cidara Therapeutics press release ( NASDAQ: CDTX ): Q1 GAAP EPS of $0.03 beats by $0.07 . Revenue of $25.99M (+265.5% Y/Y) beats by $7.31M . For further details see: Cidara Therapeutics GAAP EPS of $0.03 beats by $0.07, revenue of $...
CDTX - Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter en...

CDTX - Cidara Therapeutics: Promising Developments And A Speculative 'Buy' Recommendation (Rating Upgrade)

2023-05-03 18:23:18 ET Summary Cidara Therapeutics, a biotech firm focused on long-acting therapeutics for severe illnesses, received FDA approval for its antifungal drug, Rezafungin, triggering $20 million in milestone payments. Early Phase 2a trial results suggest CD388, develop...

CDTX - Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) --  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, is delivering two oral presentations highlighting n...
Previous 10 Next 10